Malcov Mira, Gold Veronica, Peleg Sagit, Frumkin Tsvia, Azem Foad, Amit Ami, Ben-Yosef Dalit, Yaron Yuval, Reches Adi, Barda Shimi, Kleiman Sandra E, Yogev Leah, Hauser Ron
Wolfe PGD-Stem Cell Lab, Racine IVF Unit Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Prenatal Diagnosis Unit, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Reprod Biol Endocrinol. 2017 Apr 26;15(1):31. doi: 10.1186/s12958-017-0247-4.
The study is aimed to describe a novel strategy that increases the accuracy and reliability of PGD in patients using sperm donation by pre-selecting the donor whose haplotype does not overlap the carrier's one.
A panel of 4-9 informative polymorphic markers, flanking the mutation in carriers of autosomal dominant/X-linked disorders, was tested in DNA of sperm donors before PGD. Whenever the lengths of donors' repeats overlapped those of the women, additional donors' DNA samples were analyzed. The donor that demonstrated the minimal overlapping with the patient was selected for IVF.
In 8 out of 17 carriers the markers of the initially chosen donors overlapped the patients' alleles and 2-8 additional sperm donors for each patient were haplotyped. The selection of additional sperm donors increased the number of informative markers and reduced misdiagnosis risk from 6.00% ± 7.48 to 0.48% ±0.68. The PGD results were confirmed and no misdiagnosis was detected.
Our study demonstrates that pre-selecting a sperm donor whose haplotype has minimal overlapping with the female's haplotype, is critical for reducing the misdiagnosis risk and ensuring a reliable PGD. This strategy may contribute to prevent the transmission of affected IVF-PGD embryos using a simple and economical procedure.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. DNA testing of donors was approved by the institutional Helsinki committee (registration number 319-08TLV, 2008). The present study was approved by the institutional Helsinki committee (registration number 0385-13TLV, 2013).
本研究旨在描述一种新策略,该策略通过预先选择单倍型与携带者不重叠的供体,提高使用供精的患者中植入前基因诊断(PGD)的准确性和可靠性。
在PGD之前,对常染色体显性/ X连锁疾病携带者突变侧翼的4 - 9个信息性多态性标记进行检测。只要供体重复序列的长度与女性的重叠,就对额外的供体DNA样本进行分析。选择与患者重叠最少的供体进行体外受精(IVF)。
17名携带者中有8名,最初选择的供体标记与患者等位基因重叠,每位患者另外对2 - 8名供精者进行了单倍型分析。额外供精者的选择增加了信息性标记的数量,并将误诊风险从6.00%±7.48降低至0.48%±0.68。PGD结果得到证实,未检测到误诊。
我们的研究表明,预先选择单倍型与女性单倍型重叠最少的供精者,对于降低误诊风险和确保可靠的PGD至关重要。该策略可能有助于通过简单且经济的程序防止受影响的IVF - PGD胚胎的传递。
在涉及人类受试者的研究中进行的所有程序均符合机构和/或国家研究委员会的伦理标准以及1964年《赫尔辛基宣言》及其后续修订版或类似的伦理标准。供体的DNA检测获得了机构赫尔辛基委员会的批准(注册号319 - 08TLV,2008年)。本研究获得了机构赫尔辛基委员会的批准(注册号0385 - 13TLV,2013年)。